Real-World Clinical Outcomes and Health Care Utilization in Patients With Severe Tricuspid Regurgitation
Over 3 years of follow-up, patients with severe TR had high rates of death and adverse clinical events and incurred substantial health care costs. Longer-term data regarding the impact of transcatheter interventions for severe TR on clinical outcomes and costs are needed to better understand the value of these novel therapies.
Authors
- Sarah Mollenkopf (ORCID: https://orcid.org/0000-0001-9214-2492)
- Candace Gunnarsson (ORCID: https://orcid.org/0000-0003-0723-585X)
- Lisa K. Kemp (ORCID: https://orcid.org/0000-0003-4039-1512)
- Colin M. Barker (ORCID: https://orcid.org/0000-0002-7904-0501)
- Michael P. Ryan (ORCID: https://orcid.org/0000-0002-7207-7926)
- Mahesh V. Madhavan (ORCID: https://orcid.org/0000-0002-7740-1481)
- David Jonathan Cohen (ORCID: https://orcid.org/0000-0001-9163-724X)
Institutions
- NewYork–Presbyterian Hospital (US)
- New York Hospital Queens (US)
- St. Francis Hospital (US)
- Clinical Trial and Consulting (US)
- Cardiovascular Research Foundation (US)
- Edwards Lifesciences (United States) (US)
- Orange Regional Medical Center (US)
- Columbia University (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Structural Heart
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1016/j.shj.2025.100463
- Citations
- 2
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Edwards Lifesciences